<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32969758</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3-4</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS.</ArticleTitle><Pagination><StartPage>287</StartPage><EndPage>299</EndPage><MedlinePgn>287-299</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1822410</ELocationID><Abstract><AbstractText>To evaluate safety, dose response, and preliminary efficacy of <i>reldesemtiv</i> over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). <i>Methods:</i> Patients (&#x2264;2 years since diagnosis) with slow upright vital capacity (SVC) of &#x2265;60% were randomized 1:1:1:1 to <i>reldesemtiv</i> 150, 300, or 450&#x2009;mg twice daily (bid) or placebo; active treatment was 12 weeks with 4-week follow-up. Primary endpoint was change in percent predicted SVC at 12 weeks; secondary measures included ALS Functional Rating Scale-Revised (ALSFRS-R) and muscle strength mega-score. <i>Results:</i> Patients (<i>N</i>&#x2009;=&#x2009;458) were enrolled; 85% completed 12-week treatment. The primary analysis failed to reach statistical significance (<i>p</i>&#x2009;=&#x2009;0.11); secondary endpoints showed no statistically significant effects (ALSFRS-R, <i>p</i>&#x2009;=&#x2009;0.09; muscle strength mega-score, <i>p</i>&#x2009;=&#x2009;0.31). Post hoc analyses pooling all active <i>reldesemtiv</i>-treated patients compared against placebo showed trends toward benefit in all endpoints (progression rate for SVC, ALSFRS-R, and muscle strength mega-score (nominal p values of 0.10, 0.01 and 0.20 respectively)). <i>Reldesemtiv</i> was well tolerated, with nausea and fatigue being the most common side effects. A dose-dependent decrease in estimated glomerular filtration rate was noted, and transaminase elevations were seen in approximately 5% of patients. Both hepatic and renal abnormalities trended toward resolution after study drug discontinuation. <i>Conclusions:</i> Although the primary efficacy analysis did not demonstrate statistical significance, there were trends favoring <i>reldesemtiv</i> for all three endpoints, with effect sizes generally regarded as clinically important. Tolerability was good; modest hepatic and renal abnormalities were reversible. The impact of <i>reldesemtiv</i> on patients with ALS should be assessed in a pivotal Phase 3 trial. (ClinicalTrials.gov Identifier: NCT03160898).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>The Eleanor and Lou Gehrig ALS Center, The Neurological Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Carlayne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lechtzin</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cockroft</LastName><ForeName>Bettina M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Cytokinetics, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cytokinetics, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cytokinetics, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolff</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Cytokinetics, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Fady I</ForeName><Initials>FI</Initials><AffiliationInfo><Affiliation>Cytokinetics, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodkin</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Benjamin R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Atrium Health Neurosciences Institute-Carolinas Neuromuscular/ALS MDA Care Center, Charlotte, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caress</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wake Forest Health Sciences, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHU de Qu&#xe9;bec, Universit&#xe9; Laval, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fee</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>The ALS &amp; Neuromuscular Center, UCI Health, Orange, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Trinity College, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayat</LastName><ForeName>Ghazala</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>St. Louis University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiman-Patterson</LastName><ForeName>Terry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heitzman</LastName><ForeName>Daragh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Texas Neurology, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Royal Brisbane and Women's Hospital, Herston, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>Chafic</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolb</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Wexner Medical Center, Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St. Joseph's Hospital and Medical Center, Neurological Institute, AZ, USA Barrow Phoenix.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matte</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Jesus S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Hospital San Rafael, Madrid, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Needham</LastName><ForeName>Merrilee</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Perron Institute, Department of Neurology, Fiona Stanley Hospital, The University of Notre Dame Australia, Murdoch University, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bjorn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1725-9866</Identifier><AffiliationInfo><Affiliation>Mayo Clinic Florida, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Neurology Associates, Lincoln, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulley</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Florida, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quan</LastName><ForeName>Dianna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Colorado Denver, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezania</LastName><ForeName>Kourosh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Chicago Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Kerri L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-5820-2428</Identifier><AffiliationInfo><Affiliation>University of Saskatchewan, Saskatoon, SK, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Flinders Medical Centre, Bedford Park, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Penn State Hershey Medical Center, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Statland</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultan</LastName><ForeName>Shumaila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swenson</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Leonard H Van Den</ForeName><Initials>LHVD</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Tuan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whyte-Rayson</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS/Neuromuscular Clinic Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudnicki</LastName><ForeName>Stacy A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Cytokinetics, Inc, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03160898</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Randomized clinical trial</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">reldesemtiv</Keyword></KeywordList><CoiStatement>Declaration of interest. JMS received personal compensation from Avexis, Biogen, Brainstorm, Cytokinetics, Mitsubishi Tanabe Pharma America, Neurosense, Orphazyme, Otsuka, and Revalesio; and research support from Amylyx, Brainstorm, Cytokinetics, Medicinova, and Mitsubishi Tanabe Pharma America. JAA served as a consultant for ALS Pharma, Avexis, Biogen and Cytokinetics; is a former employee of Cytokinetics; and received research support from Biogen, Neuraltus, Orion, Roche, Novartis. AG served as a consultant for Alexion, AL-S Pharma, Biogen, Calico, and Cytokinetics. CJ has received grant support from Amylyx and Cytokinetics; served on the DSMB for Anelixis, Brainstorm, and Mallinckrodt; and served as a consultant for Cytokinetics, ITF Pharma, and Mitsubishi Tanabe Pharma America. NL is a consultant for Cytokinetics. TMM is a consultant for Cytokinetics and Disarm Therapeutics; has licensing agreements with C2N Diagnostics and Ionis Pharmaceuticals; and serves on the advisory board and receives research support from Biogen. CB served (uncompensated) on an advisory board for Argenx. BRB has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from AB Science, Biogen, Biohaven, California ALS Research Summit, Cytokinetics, ITF Pharma, Mitsubishi Tanabe Pharma American, and for serving in an editorial capacity for <i>American Journal of Managed Care</i>; and has received research support from Acceleron, Alexion, Biogen, Biohaven, Boston Scientific, Center for Disease Control, Cytokinetics, ITF Pharma, Medicinova, Mitsubishi Tanabe Pharma America, Neuraltus, Orion, and Santhera. DF has served on an advisory board for Biogen Scientific. OH has received consulting fees from Novartis; research funding from Biogen, Cytokinetics, Ionis and Merck; and is Editor-in-Chief of <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.</i> GH served on speaker&#x2019;s bureau and as a consultant for Alexion, CSL Behring, KabaFusion, and Mitsubishi Tanabe Pharma. TH-P has received consulting fees from Amylyx, Cytokinetics, ITF Pharma and Mitsubishi Tanabe Pharma. RDH served on SMA advisory board for Biogen and Pompe advisory board (Sanofi). WJ received honoraria from Mitsubishi Tanabe Pharma Canada advisory board; and served on clinical trials for Alexion Pharmaceuticals, ALS-Pharma SA, Biogen, Cytokinetics, Mallinckrodt, Mitsubishi Tanabe Pharma Development America, and Orion. CK served on advisory boards for Acceleron, Akcea, Alexion, Alnylam, Argenx, Biogen, CSL Behring, Cytokinetics, and Sanofi Genzyme. MCK receives funding from National Health &amp; Medical Research Council of Australia. SJK served as a consultant for AveXis, Biogen, and Roche and receives grant support from AveXis. GM has research contracts with Cytokinetics, Mallinckrodt, Orion, and University of Calgary; and received fees for speaking, advisory board, and travel from Mitsubishi Tanabe Pharma Canada. MN received honoraria from Biogen, Novartis, and Sanofi for chairing and speaking at professional development meetings. BO serves as a consultant for Biogen, Biohaven, MediciNova, Mitsubishi, and Tsumura; and receives research funding from Biogen, Eisai, Genentech, Mitsubishi, and Orion. EPP received clinical trial and research funding from ALS Association, Iron Horse Diagnostics, and NIH/CDC, and served as consultant to Avanir Pharmaceuticals, Biohaven Pharmaceuticals, Cytokinetics, ITF Pharma, Mitsubishi Tanabe Pharma America, and Otsuka America. MP received honoraria from Argenx, Bioproducts Laboratory, CSL Behring, Catalyst, Grifols, and Stealth BioTherapeutics. DQ received research funding from Alnylam, Argenx, Cytokinetics, Flex Pharma, and Momenta. ZS is a consultant for Biogen and Cytokinetics, and received research support from Biogen. JS received grant funding from FSHD Society, Friends of FSH Research, MDA, and NINDS; is a consultant or on advisory boards for Acceleron, Dyne, FACIO, Fulcrum, Genzyme, Mitsubishi Tanabe Pharma, and Sarepta. AS received research support from Amylyx. LHV serves on scientific advisory boards for Biogen, Cytokinetics, and Orion; received an educational grant from Takeda; serves on the editorial boards of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and the Journal of Neurology, Neurosurgery, and Psychiatry; and receives research support from the Netherlands ALS Foundation, and The Netherlands Organization for Health Research and Development (Vici Scheme, JPND [SOPHIA, STRENGTH, ALSCare]). MW received funding from ALSA Association and ALS Finding a Cure; is a speaker for NuFactor; and is a consultant for Argenx and Ra Pharma. JW received research funding from Cytokinetics as part of the study. LZ received honoraria from Biogen, Cytokinetics, and Mitsubishi Tanabe Pharma. BMC owns stock in and was an employee of Cytokinetics during the conduct of the study. LM, JW, AAW, FIM, and SAR own stock and are employees of Cytokinetics. JC, AD, SAG, NAG, DH, LK, SL, JSM, GLP, KR, KLS, DS, CS, SS, TV, SV, and AW-R report no relevant disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32969758</ArticleId><ArticleId IdType="mid">NIHMS1695533</ArticleId><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, et al. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:430&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22591195</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Watson ML, Meng L, Wolff AA. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14:574&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">23952636</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Wolff AA, Meng L. The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:582&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23952600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI. A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics. 2015;12:455&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404445</ArticleId><ArticleId IdType="pubmed">25742919</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016; 17:426&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26982815</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, et al. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 0:1&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">31081694</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018;57:729&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6681065</ArticleId><ArticleId IdType="pubmed">29150952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, et al. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2014;50:925&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260123</ArticleId><ArticleId IdType="pubmed">24634285</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3&#x2013;95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786581</ArticleId><ArticleId IdType="pubmed">22743675</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12: 1059&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071495</ArticleId><ArticleId IdType="pubmed">20363190</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, et al. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: possible mitochondrial biomarker target engagement. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:345&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610861</ArticleId><ArticleId IdType="pubmed">25832828</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, et al. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol. 2018;75: 58&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833488</ArticleId><ArticleId IdType="pubmed">29181534</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 2011; 77:973&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171956</ArticleId><ArticleId IdType="pubmed">21813790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11: 178&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP. Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort. Muscle Nerve. 2018;57:937&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">29244213</ArticleId></ArticleIdList></Reference><Reference><Citation>Enache I, Pistea C, Fleury M, Schaeffer M, Oswald-Mammosser M, Echaniz-Laguna A, et al. Ability of pulmonary function decline to predict death in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:511&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28728441</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnicki SA, Andrews JA, Malik FI, Wolff AA, Day JW. Update of CY 5021: a phase 2 clinical trial of reldesemtiv, a fast skeletal muscle troponin activator (FSTA), for the potential treatment of spinal muscular atrophy. Presented at the 2018 SMA Researcher Meeting, June 14&#x2013;16, 2018, Dallas, Texas.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>